Complexo Hospitalario Universitario da Coruña-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2023

  1. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial

    European urology oncology, Vol. 6, Núm. 1, pp. 58-66

2022

  1. Non-metastatic castration-resistant prostate cancer: management recommendations

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2011

  1. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    European Urology, Vol. 60, Núm. 3, pp. 423-430

2009

  1. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2008

  1. Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

    European Urology, Vol. 53, Núm. 5, pp. 992-1002